摘要
目的分析康莱特注射液联合新辅助化疗治疗肺癌的效果。方法选取本院2017年1月至2019年3月收治的56例肺癌患者,按照随机数字表法分为观察组和对照组,每组各28例。对照组仅采用新辅助化疗手段,观察组在对照组的基础上,加用康莱特注射液进行治疗。治疗三个疗程(一个疗程21天),观察并记录观察组和对照组的临床缓解率、治疗前后在T细胞亚群(CD3^+、CD4^+、CD8^+、CD4^+/CD8^+)里的变化情况、生活质量及不良反应情况。结果观察组的临床缓解率明显高于对照组(P<0.05);观察组治疗后CD3^+、CD4^+、CD4^+/CD8^+水平比治疗前升高,CD8^+下降,且观察组治疗后CD3^+、CD4^+、CD4^+/CD8^+明显高于对照组,CD8^+低于对照组,差异有统计学意义(P<0.05);治疗后观察组患者社会关系、心理情况、精神情况和治疗情况分值都比对照组高(P<0.05);观察组疲乏发生率46.43%比对照组的100.00%低(P<0.05),两组恶心呕吐、腹泻发生率无统计学意义(P>0.05)。结论肺癌患者采用康莱特注射液并联合新辅助化疗治疗的手段临床效果好,能明显提高患者的免疫功能,减少患者的不良反应,改善患者的生活质量,值得大力推广。
Objective To analyze the effects of Kanglaite injection combined with neoadjuvant chemotherapy in the treatment of lung cancer.Methods A total of 56 patients with lung cancer admitted to the hospital from January 2017 to March2019 were selected and divided into observation group and control group according to the random number table method,with 28 cases in each group.Control group was only given neoadjuvant chemotherapy,and observation group was additionally given Kanglaite injection on the basis of control group,and they were treated for 3 courses of treatment(one course of 21 d).The clinical remission rate and changes in T cell subsets(CD3^+,CD4^+,CD8^+,CD4^+/CD8^+),quality of life and adverse reactions before and after treatment were observed and recorded in observation group and control group.Results The clinical remission rate in observation group was significantly higher than that in control group(P<0.05).The levels of CD3^+,CD4^+and CD4^+/CD8^+after treatment were increased compared with those before treatment while the level of CD8^+was decreased,and the levels of CD3^+,CD4^+and CD4^+/CD8^+after treatment in observation group were significantly higher than those in control group while the level of CD8^+was lower than that in control group(P<0.05).After treatment,the scores of social relations,psychological status,mental status and treatment status in observation group were higher than those in control group(P<0.05).The incidence rate of fatigue in observation group was lower than that in control group(46.43%vs 100.00%)(P<0.05),and there were no significant differences in the incidence rates of nausea and vomiting and diarrhea between the two groups(P<0.05).Conclusion Kanglaite injection combined with neoadjuvant chemotherapy has good clinical effects on patients with lung cancer.It can significantly improve the immune function,reduce the adverse reactions and improve the quality of life of patients.Thus it is worth promoting.
作者
张智辉
ZHANG Zhi-hui(Department of Respiratory Medicine,Pingdingshan First People’s Hospital,Pingdingshan 467000,Henan Province,China)
出处
《罕少疾病杂志》
2020年第5期6-7,15,共3页
Journal of Rare and Uncommon Diseases
关键词
康莱特注射液
新辅助化疗
肺癌
临床疗效
Kanglaite Injection
Neoadjuvant Chemotherapy
Lung Cancer
Clinical Efficacy
